Global Health Ltd
Global Health Ltd
HealthcareGlobal Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]
Global Health (Medanta) offers strong revenue growth at 18% CAGR over 3 years and exceptional profit growth of 81% CAGR over 5 years, backed by 86% analyst buy ratings. However, the premium valuation at 61x PE and 8.54x PB warrants caution, making it suitable for long-term investors comfortable with a quality-at-a-premium approach.
Key Fundamentals
SmallcapHospitalsHealthcare ServicesTechnical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 80.7% CAGR over last 5 years
Weaknesses
1- Stock is trading at 8.95 times its book value
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 3d agoGlobal Health (Medanta) offers strong revenue growth at 18% CAGR over 3 years and exceptional profit growth of 81% CAGR over 5 years, backed by 86% analyst buy ratings. However, the premium valuation at 61x PE and 8.54x PB warrants caution, making it suitable for long-term investors comfortable with a quality-at-a-premium approach.
- Exceptional 5-year compounded profit growth of 81% CAGR demonstrates strong operating leverage and scalability
- 86% analyst buy consensus (12 out of 14 analysts) with zero sell ratings signals strong institutional confidence
- Consistent 3-year compounded sales growth of 18% indicates robust demand for healthcare services
- TTM revenue growth of 19% shows continued momentum in topline expansion
- Stable ROE of 15-16% over 3 years reflects consistent capital efficiency for a hospital chain
- Market cap of Rs 34,101 Cr provides adequate liquidity and index eligibility potential
- Stock CAGR of 25% over 3 years indicates sustained investor wealth creation
- Long-term 10-year sales CAGR of 12% shows the company has weathered multiple economic cycles
- PE ratio of 61x is significantly above the hospital sector average of 35-40x, leaving limited margin of safety
- Price-to-book ratio of 8.54x indicates the stock is heavily priced for perfection with little room for execution misses
- TTM profit growth has decelerated sharply to 7% versus 20% CAGR over 3 years, signaling potential margin pressure
- Dividend yield of just 0.04% offers virtually no income cushion during market corrections
- 1-year stock CAGR of only 12% versus 3-year CAGR of 25% suggests momentum is fading
- Profit growth deceleration from 81% (5-year CAGR) to 20% (3-year CAGR) to 7% (TTM) shows a clear declining trajectory
- At 61x earnings, the stock needs to deliver over 25% annual profit growth to justify its valuation, which current TTM growth of 7% does not support
- ROE of 15% does not adequately compensate for the 8.54x book value premium investors are paying
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 1d ago- Medical college LOI from Haryana Jun 12
Global Health received a Letter of Intent dated June 11, 2026 from the Government of Haryana to establish a medical college with 150 MBBS seats at Medanta – The Medicity, Sector-38, Gurugram. This strengthens clinical talent pipeline and adds a new revenue vertical.
- Institutional block trade activity Jun 3
A block trade of ~1,50,070 shares was executed on NSE at ₹1,207.20 per share, totaling ₹18.12 crores. The institutional-level participation signals continued large-investor interest at current price levels.
- Active global investor engagement Jun 4
Management met institutional investors in Singapore on June 9, 2026, indicating active efforts to broaden the international shareholder base.
- Multiple analyst meets scheduled Jun 18
Global Health management scheduled back-to-back analyst and investor meetings across Noida, Gurugram, and Lucknow from June 11 through June 26, organized by JP Morgan, IIFL Capital, Ambit, Emkay, and Prudent Corporate Advisory. No unpublished price sensitive information to be shared.
TL;DR: Global Health is actively courting institutional investors domestically and internationally with a packed schedule of analyst meetings through June 2026. The medical college LOI from Haryana government is a meaningful positive, expanding Medanta's ecosystem into medical education with 150 MBBS seats. No material headwinds emerged in the period. The trend is stable-to-improving, with management visibility efforts and a strategic expansion into education signaling confidence in long-term growth.
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 707 | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 |
| Expenses | 540 | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 |
| Operating Profit | 167 | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 |
| OPM % | 24% | 24% | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% |
| Other Income | 25 | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 |
| Interest | 20 | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 |
| Depreciation | 38 | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 |
| PBT | 133 | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 |
| Tax % | 24% | 28% | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% |
| Net Profit | 101 | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 |
| EPS in Rs | 3.77 | 3.8 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 |
Profit & Loss
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 |
| Expenses | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,491 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 919 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 21% |
| Other Income | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 98 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 79 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 |
| PBT | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | 23% |
| Net Profit | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 |
| EPS in Rs | 35.1 | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 20.7 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,908 |
| Borrowings | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 1,190 |
| Other Liabilities | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
| Fixed Assets | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Other Assets | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,975 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
Cash Flow
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Investing | -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | -1,089 |
| Financing | -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| Free Cash Flow | 71 | -81 | -133 | -13 | 100 | 38 | 409 | 335 | 110 | -263 |
| CFO/OP | 108 | 93 | 135 | 121 | 131 | 89 | 118 | 98 | 89 | 91 |
Ratios
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 | 34 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 | 29 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 | 89 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 | -26 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 | -7 |
| ROCE % | — | — | 6% | 6% | 5% | 15% | 17% | 20% | 20% | 17% |
Documents
Frequently Asked Questions about Global Health Ltd
What does Global Health Ltd do?
Where is Global Health Ltd (MEDANTA) listed?
Which sector does Global Health Ltd belong to?
What is the market capitalisation of Global Health Ltd?
What is the PE ratio of Global Health Ltd?
What is the 52-week high and low of Global Health Ltd?
Does Global Health Ltd pay dividends?
What is the Return on Equity (ROE) of Global Health Ltd?
How can I research Global Health Ltd on Tapetide?
Company Information
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]